Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
February 28 2023 - 9:00AM
Business Wire
The New Solution uses SOPHiA DDM™ and aims
to Benefit Cancer Research, Clinical Studies and Patient
Care
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space, today announced that Synergy Oncology,
part of Synergy Laboratories, a full-service diagnostic laboratory
based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new
cancer profiling solution. The combination of technology from
Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology
portfolio while helping to further the U.S. oncology market.
Synergy Oncology, which specializes in the use of innovative
platforms to improve patient care, will pair SOPHiA DDM™ for
Hereditary Cancers Solution with their state-of-the-art laboratory
technologies to launch Totality, a comprehensive end-to-end
solution for tumor profiling that will benefit cancer research,
clinical studies, and patient care.
“Our mission at SOPHiA GENETICS is to democratize data-driven
medicine by increasing accessibility to synthesized, digestible
data in this space,” said Ken Freedman, Chief Revenue Officer,
SOPHiA GENETICS. “Synergy is known to be a best-in-class facility
and their use of the SOPHiA DDM™ is an important step in creating
cancer profiling solutions that will progress research and
treatments of hereditary cancers for the medical community.”
“Our decision to collaborate with SOPHiA GENETICS was simple,”
said Joseph Cohil, Head of Synergy Oncology. “Our collaboration
with SOPHiA GENETICS will accelerate Synergy’s leading hereditary
cancer technology to the forefront of patient outcomes.”
The use of next generation sequencing (NGS) is prevalent in the
detection of biomarkers for hereditary cancers but comes with a
vast and complex dataset for analysis. The SOPHiA DDM™ for
Hereditary Cancers Solution uses Artificial Intelligence and
machine learning with patented technologies to analyze raw NGS
data, streamlining it for simplified interpretation, and expedited
reporting. The SOPHiA DDM™ platform can serve as a one-stop
solution for Synergy Laboratories as it looks to scale into other
oncology offerings.
Synergy’s new Totality product analyzes genes from solid tumor
tissue, and through the use of SOPHiA DDM™ for Hereditary Cancers,
it provides physicians with a compact report that matches detected
molecular alterations with FDA approved therapies and clinical
trials. The pairing of SOPHiA DDM™ for Hereditary Cancers with
Synergy Oncology’s technology is designed to give experts the
ability to analyze and interpret findings from NGS data with
confidence, turning high-quality data into valuable insights for
researchers and care providers. Synergy Oncology offers the most
comprehensive NGS kit of its kind, including liquid biopsy testing,
hereditary testing, and myeloid malignancies.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
About Synergy Laboratories
Synergy Laboratories is a full-service diagnostic laboratory
that utilizes a wide range of innovative platforms to improve
patient care. Founded in 2015, Synergy’s mission is to ethically
serve the healthcare sector and give healthcare providers quality
service and accurate results. Synergy Oncology is a business unit
of Synergy Laboratories headquartered in Mobile, Alabama. The
Company offers an extensive oncology diagnostic testing menu to the
cancer-related healthcare sector in the United States, including,
hospital and private pathology laboratories, oncologists,
biopharmaceutical partners, academia, CRO, and more. Synergy
Oncology specializes in genomics, enabling the personalization of
cancer treatments. In recent years, Synergy has continued to invest
in the latest technology to serve their ever-growing client base.
This includes many exciting announcements to follow. To learn more,
visit www.synergytesting.com or stay up to date with Synergy
Oncology on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228005666/en/
Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024